Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Aimei Health Technology Co., Ltd Ordinary Share Market Cap
The Aimei Health Technology Co., Ltd Ordinary Share (AFJK) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered AFJK. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for AFJK is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned AFJK 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Aimei Health Technology Co., Ltd Ordinary Share to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AFJK. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AFJK.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
2024
Staff Count
0
Country
United States
Sector/Industry
Financial Services/Shell Companies
CEO
Mr. Junheng Xie
Market Cap
$94.7M
In 2023, AFJK generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AFJK's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 20 Jun 2024
Sentiment - NEUTRAL
Source - InvestorPlace
Summary - Aimei Health Technology (NASDAQ: AFJK) stock is down despite announcing a $1.6 billion SPAC merger with United Hydrogen Group, which will go public with a new ticker on Nasdaq.
Why It Matters - Aimei Health's stock decline despite a significant SPAC merger indicates potential investor skepticism about the deal's value or future performance, impacting market sentiment and investment strategies.
Thu, 20 Jun 2024
Sentiment - POSITIVE
Source - Reuters
Summary - United Hydrogen Group plans to list on Nasdaq through a blank-check merger, valuing the company at $1.6 billion.
Why It Matters - United Hydrogen Group's Nasdaq listing via a SPAC merger at $1.6 billion signals growth potential in the green energy sector, attracting investor interest and indicating market confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
